NCT07218172Active, not recruiting
Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
A retrospective, observational, one arm, single country study, using the computerized database of Maccabi Health Services (MHS). The study will include adult patients who initiated benralizumab treatment for SEA between January 1, 2019, and March 31, 2024. The study population will include both biologic-naive and biologic-experienced patients. Patients will be followed from 12 months before the index date until the earliest of the following dates: switching, death, leaving MHS or end of the study follow-up period (June 30, 2024).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 197 (estimated)
- First submitted
- 29 Sept 2025
- Start date
- 24 Mar 2025
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Asthma
- NCT number
- NCT07218172
What you commit to
- Study type: Observational
- Planned participants: 197
- From 24 Mar 2025 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received benralizumab for indication other than asthma according to MHS drugs authorization center.
- \- currently or recently included in a clinical trial according to the ICD-9 diagnosis code V70.7) and the corresponding internal MHS codes
Who the study is looking for
- An authorization from MHS drugs authorization center for benralizumab, with a diagnosis of asthma (ICD-9 code 493.X and the corresponding internal MHS diagnosis codes for SA). Having an authorization indicates that patients have severe eosinophilic asthma and fulfil the GINA definition of severe asthma as well as additional local reimbursement criteria.
- At least one purchase of benralizumab for the first time between January 1 2019 and March 31 2024.
- Age ≥18 years on the index date.
- MHS members for at least 12 months before the index date.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Tel Aviv | Israel | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.